Skip Navigation

Oncology

We are always looking to collect samples from patients with malignant melanoma, osteosarcoma, and lymphoma for research purposes. While collecting these samples will not directly benefit the patient, the information gained from these samples will aid in the creation and development of future cancer therapies.

Evaluation of a new therapy, Leukothera, for the treatment of canine hematopoietic tumors (lymphoma, leukemia and multiple myeloma)

TitleEvaluation of a new therapy, Leukothera, for the treatment of canine hematopoietic tumors (lymphoma, leukemia and multiple myeloma)
Contact Person Heather Wilson, DVM, DACVIM (Oncology)
Hospital Phone: 979-845-2351
Email: oncology@cvm.tamu.edu
Species Canines
Inclusion Criteria and General Background Information

Dogs with a newly diagnosed or first relapse of any hematopoietic tumor (lymphoma, multiple myeloma or leukemia) with systemic disease (at least a stage III lymphoma) are eligible to enroll. Dogs must weigh at least 10 kg (22 lbs).

Exclusion Criteria

Dogs with significant concurrent disease are excluded from this study.

Owner Commitments

Dogs will be required to visit Texas A&M University weekly for 5 weeks for treatment and therapy. The initial visit costs are not covered by the study as we determine if your dog is eligible; however, once enrolled, all fees associated with the study will be covered. Dogs will be required to come on the same day each week for approximately 3 hours each visit to be examined, run blood work and administer therapy.

Financial Incentives

All costs associated with therapy after enrollment are covered by the study. There is an additional $750 to help with any possible side effects your dog may experience. Any costs beyond $750 for side effects will be the responsibility of the owner.

This trial is currently open and enrolling

Evaluation of biomarkers as risk factors for lymphoma in Golden Retrievers

TitleEvaluation of biomarkers as risk factors for lymphoma in Golden Retrievers
Contact Person Heather Wilson, DVM, DACVIM (Oncology)
Hospital Phone: 979-845-2351
Email: oncology@cvm.tamu.edu
Species Canines
Inclusion Criteria and General Background Information

Any golden retriever with lymphoma may qualify for this trial.

Exclusion Criteria

Dogs without lymphoma or with other tumors may not qualify for this trial.

Owner Commitments

Dogs will participate with a cheek swab on a one time bases. Participation in this trial is expected to add no more than 30 minutes to the total visit time.

Financial Incentives

There is no cost for participation in this trial. There are no financial benefits for participation in this trial.

This trial is currently open!

Evaluation of DNA methylation patterns as risk factors for lymphoma in Golden Retrievers

TitleEvaluation of DNA methylation patterns as risk factors for lymphoma in Golden Retrievers
Contact Person Heather Wilson, DVM, DACVIM (Oncology)
Hospital Phone: 979-845-2351
Email: oncology@cvm.tamu.edu
Species Canines
Inclusion Criteria and General Background Information

Any golden retriever with B cell lymphoma may qualify for this trial.

Exclusion Criteria

Dogs without lymphoma or with other tumors may not qualify for this trial.

Owner Commitments

Participation may include a biopsy of the lymph node, a fine needle aspirate of the lymph node and a blood sample. Participation may add 1-2 hours to the visit.

Financial Incentives

There is no cost for participation in this trial. There are no financial benefits for participation in this trial.

This trial is currently open!

Pilot Study of AuroLase® Therapy for the Treatment of Solid Tumors in Canine and Feline Patients

TitlePilot Study of AuroLase® Therapy for the Treatment of Solid Tumors in Canine and Feline Patients
Contact Person Micheal Deveau, DVM, MS, DACVR (Radiation Oncology)
Phone: 979-845-2351
Email: oncology@cvm.tamu.edu
Species Canines and Felines
Inclusion Criteria and General Background Information

Any treatment naïve, recurrent, and/or refractor dog with a confirmed diagnosis or a soft tissue sarcoma or squamous cells carcinoma limited to the head and neck, oral cavity, or limb is eligible for enrollment. Any cat with a confirmed diagnosis or an oral squamous cell carcinoma that has not received treatment, has recurrent disease, or has not responded to treatment is eligible for enrollment.

Exclusion Criteria

Dogs and cats with significant concurrent disease are excluded from this study. Poor candidates for anesthesia are excluded.

Owner Commitments

The AuroLase® therapy will take place over two consecutive days at Texas A&M University. Treatment on day one will take approximately 60 minutes and treatment on day two will take approximately 90 minutes. Study patients will be returned to their owners between day one and two, and at the end of the day on day 2. The study requires routine follow up visits starting two weeks after treatment and then once a month for 3 months. Follow up visits will take approximately 60 minutes.

Financial Incentives

Owners are responsible for costs associated with diagnostics, staging, and other complimentary treatments, and any potential complications not associated directly with AuroLase® Therapy. There are no other financial obligations by the owner to Texas A&M University for participation in this study.

This trial is currently open and enrolling

Use of desmopressin to possibly decrease the metastatic potential of tumors at the time of surgery in dogs

TitleUse of desmopressin to possibly decrease the metastatic potential of tumors at the time of surgery in dogs
Contact Person Heather Wilson, DVM, DACVIM (Oncology)
Hospital Phone: 979-845-2351
Email: oncology@cvm.tamu.edu
Species Canine
Inclusion Criteria and General Background Information
  • The diagnosis and medical evaluation for the cancer in your dog is not part of this study.
  • Dogs that are surgical candidates at the Veterinary Medical Teaching Hospital (VMTH), as part of their selected treatment options, are eligible to participate in this study if they meet these additional requirements.
  • Dogs must be greater than 1 year of age and weigh more than 10 pounds.
  • Dogs must present to the VMTH Oncology Service (TAMU) with a tentative cytological or definitive histological diagnosis of osteosarcoma, anal sac adenocarcinoma, or hemangiosarcoma.
  • Dogs must have no clinical evidence or suspicion of Diabetes Insipidus.
  • Dogs must not have received previously chemotherapy for 1 week, radiation therapy for at least 2 weeks, and no experimental therapies for at least 2 weeks.
  • Dogs must have a performance score of 0-1 [0= normal activity, 1= restrictive activity: decreased activity from pre-disease state, 2= ambulatory and capable of all activities of daily life (eating, going outside the bathroom) Up and about more than 50% of waking hours].
Exclusion Criteria
  • Dogs with significant concurrent disease are excluded from this study. Dogs must have no clinical evidence or suspicion of Diabetes Insipidus.
  • Dogs must not have received previously chemotherapy for 1 week, radiation therapy for at least 2 weeks, and no experimental therapies for at least 2 weeks.
Owner Commitments

Dogs receiving surgery for osteosarcoma, anal sac adenocarcinoma, or hemangiosarcoma will receive an intravenous dose of desmopressin or an equivalent volume of saline (placebo) 30 min before and 12 hours after surgery. Each dog will participate on a one-time basis and this process will take approximately 5 minutes.. However, study personnel will contact you monthly (if you are not receiving treatment through TAMU) to see how your dog is doing for up to 24 months. Follow up treatments and rechecks for the cancer (which are not part of this study) may be performed elsewhere and do not have to occur at Texas A&M.

Financial Incentives

All costs associated with the administration of desmopressin or saline are covered by the study. All other charges are the responsibility of the owner.

This trial is currently open!

Evaluation of a new drug for the treatment of canine appendicular osteosarcoma

TitleEvaluation of a new drug for the treatment of canine appendicular osteosarcoma
Contact Person Heather Wilson, DVM, DACVIM (Oncology)
Hospital Phone: 979-845-2351
Email: oncology@cvm.tamu.edu
Species Canines
Inclusion Criteria and General Background Information Dogs with a single osteosarcoma (primary bone tumor) lesion on a limb without evidence of tumor spread and no other significant health problems. Dogs may not have received any other treatments other than pain medications.  Dogs do not have to have a confirmed diagnosis of osteosarcoma to be examined for eligibility.
Exclusion Criteria

Dogs with osteosarcoma of the head, spine, or pelvis as well as dogs with spread of their tumor to other locations do not qualify for this study. Dogs that have received prior surgery, chemotherapy or radiation therapy for their osteosarcoma do not qualify. Dogs who cannot travel to TAMU for therapy do not qualify for this study.

Owner Commitments

Dogs must undergo amputation of the affected limb (standard of care treatment) to be enrolled in this study. All dogs will receive $1000 towards the cost of amputation and the costs of standard of care chemotherapy will be covered by the study. Dogs will be randomized to receive standard of care (amputation plus traditional chemotherapy) or standard of care plus a new oral drug.  All visits must occur at TAMU.  For those in the standard of care arm this means the amputation and then chemotherapy every 3 weeks for 4 total doses will be done here followed by rechecks every 8 weeks for up to 1 year. For those in the experimental treatment arm the amputation and chemotherapy (every 3 weeks for 4 doses) will be done here followed by 4 monthly overnight visits and then recheck visits every 8 weeks for up to 1 year.

Financial Incentives

There is no cost for participation in this trial. This trial is currently open!